{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:58Z","timestamp":1793656678852,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacc.2025.03.503","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T10:02:38Z","timestamp":1746439358000},"page":"1757-1770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Schueler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Panova-Noeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiane","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Prochaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Sumin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.03.503_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.0000000000000362","article-title":"Alleviation of anemia by SGLT2 inhibitors in patients with CKD: mechanisms and results of long-term placebo-controlled trials","volume":"19","author":"Packer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.03.503_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacc.2025.03.503_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102702","article-title":"Increase in hematocrit with SGLT-2 inhibitors - hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?","volume":"17","author":"Ekanayake","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jacc.2025.03.503_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.503_bib12","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.503_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13340-020-00474-2","article-title":"Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation","volume":"12","author":"Yamada","year":"2020","journal-title":"Diabetol Int"},{"key":"10.1016\/j.jacc.2025.03.503_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78734-z","article-title":"Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes","volume":"10","author":"Aberle","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.03.503_bib15","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.03.503_bib16","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: findings From DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.503_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib18","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ejhf.2731","article-title":"How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure","volume":"24","author":"Packer","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib19","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2025.03.503_bib20","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1073\/pnas.88.11.4946","article-title":"Iron-independent induction of ferritin H chain by tumor necrosis factor","volume":"88","author":"Miller","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2025.03.503_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jacc.2025.03.503_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","article-title":"Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure","volume":"11","author":"Packer","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/dom.14963","article-title":"Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes","volume":"25","author":"Packer","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.03.503_bib24","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib25","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1002\/jcp.30247","article-title":"Erythroferrone structure, function, and physiology: iron homeostasis and beyond","volume":"236","author":"Srole","year":"2021","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jacc.2025.03.503_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3324\/haematol.2019.233874","article-title":"Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure","volume":"106","author":"Robach","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2025.03.503_bib27","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2025.03.503_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.18619","article-title":"The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: a pre-post cohort study","volume":"201","author":"Zaman","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2025.03.503_bib29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/nep.13495","article-title":"Hepcidin-25\/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate","volume":"24","author":"Hara","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jacc.2025.03.503_bib30","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib31","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2215\/CJN.00100106","article-title":"Properties permitting the renal cortex to be the oxygen sensor for the release of erythropoietin: clinical implications","volume":"1","author":"Halperin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.03.503_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2021.102536","article-title":"Is the erythropoietin-erythroferrone-hepcidin axis intact in human neonates?","volume":"88","author":"Bahr","year":"2021","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jacc.2025.03.503_bib33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3389\/fimmu.2019.02315","article-title":"Immunity, inflammation and heart failure: their role on cardiac function and iron status","volume":"10","author":"Perticone","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacc.2025.03.503_bib34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCHEARTFAILURE.114.001100","article-title":"Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes","volume":"7","author":"O'Meara","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib35","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.htct.2024.04.125","article-title":"Evaluation of hepcidin-25\/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte\/reticulocyte parameters in hemodialysis patients","volume":"46(Suppl 5)","author":"Bakr","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.jacc.2025.03.503_bib36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1046\/j.1440-1746.2003.03144.x","article-title":"Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function","volume":"18","author":"Yang","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.03.503_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2362.2001.00774.x","article-title":"Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics","volume":"31","author":"Pham","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacc.2025.03.503_bib38","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/ndt\/7.12.1190","article-title":"Renal venous erythropoietin concentrations in hypertensive patients with unilateral renal disease","volume":"7","author":"Labeeuw","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.03.503_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF00581229","article-title":"A comparison of the effects of renal artery constriction and anemia on the production of erythropoietin","volume":"413","author":"Pagel","year":"1988","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jacc.2025.03.503_bib40","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3181\/00379727-125-32125","article-title":"Relationship between renal blood flow and erythropoietin production in dogs","volume":"125","author":"Fisher","year":"1967","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib41","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1253\/circj.CJ-14-1171","article-title":"Renal nerve-mediated erythropoietin release confers cardioprotection during remote ischemic preconditioning","volume":"79","author":"Oba","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2025.03.503_bib42","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.3390\/ijms22158209","article-title":"Effect of erythropoietin on the expression of murine transferrin receptor 2","volume":"22","author":"Berezovsky","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.03.503_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jacc.2004.03.052","article-title":"Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure","volume":"44","author":"van der Meer","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.503_bib44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ejhf.537","article-title":"Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure","volume":"18","author":"Nagai","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.503_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCULATIONAHA.108.844662","article-title":"Endogenous erythropoietin and outcome in heart failure","volume":"121","author":"Belonje","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.503_bib46","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.3390\/jcm13164742","article-title":"Prognostic role of tissue iron deficiency measured by stfr levels in heart failure patients without systemic iron deficiency or anemia","volume":"13","author":"Ramos-Polo","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.03.503_bib47","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","article-title":"Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure","volume":"35","author":"Jankowska","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.503_bib48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","article-title":"Iron status in patients with chronic heart failure","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.503_bib49","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14890","article-title":"Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus","volume":"9","author":"Hare","year":"2021","journal-title":"Physiol Rep"},{"key":"10.1016\/j.jacc.2025.03.503_bib50","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s44161-023-00352-5","article-title":"Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure","volume":"2","author":"Angermann","year":"2023","journal-title":"Nat Cardiovasc Res"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725059789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725059789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:58:16Z","timestamp":1749844696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725059789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0735109725059789"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.503","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}